The use of Bacillus species, particularly Bacillus clausii, as probiotics in the management of dysentery and other gastrointestinal disorders is supported by moderate scientific evidence. Several clinical studies and reviews have examined the efficacy of Bacillus probiotics in treating various forms of diarrhea, including those associated with dysentery. Bacillus clausii is widely used as a probiotic supplement, especially in parts of Asia and Europe, for both children and adults suffering from acute diarrhea, including cases caused by bacterial or viral infections.

The proposed mechanisms include the restoration of normal gut flora, competitive inhibition of pathogenic microorganisms, production of antimicrobial substances, and immunomodulatory effects. Some randomized controlled trials have shown that supplementation with Bacillus clausii can reduce the duration and severity of diarrhea, including that due to dysentery, compared to placebo. However, the overall quality and quantity of evidence are moderate; many studies have small sample sizes, and there is some heterogeneity in patient populations and outcome measures.

In summary, while the use of Bacillus species as probiotics in dysentery is not purely traditional and does have a scientific basis, the evidence is not robust enough to warrant a high rating. Nonetheless, it is commonly recommended as an adjunct to standard therapy, especially in settings where antibiotic-associated or infectious diarrhea is prevalent.